BRPI0813553A2 - composições farmacêuticas e métodos para tratamento de distúrbios do olho seco - Google Patents

composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Info

Publication number
BRPI0813553A2
BRPI0813553A2 BRPI0813553A BRPI0813553A BRPI0813553A2 BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2 BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A BRPI0813553 A BR PI0813553A BR PI0813553 A2 BRPI0813553 A2 BR PI0813553A2
Authority
BR
Brazil
Prior art keywords
methods
pharmaceutical compositions
dry eye
eye disorders
treating dry
Prior art date
Application number
BRPI0813553A
Other languages
English (en)
Inventor
Rodney Beals Channing
Woldemussie Elizabeth
John Gukasyan Hovhannes
Ma Jingwen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0813553A2 publication Critical patent/BRPI0813553A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0813553A 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco BRPI0813553A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94921607P 2007-07-11 2007-07-11
US6003208P 2008-06-09 2008-06-09
PCT/IB2008/001819 WO2009007839A1 (en) 2007-07-11 2008-07-04 Pharmaceutical compositions and methods of treating dry eye disorders

Publications (1)

Publication Number Publication Date
BRPI0813553A2 true BRPI0813553A2 (pt) 2017-05-09

Family

ID=39925011

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813553A BRPI0813553A2 (pt) 2007-07-11 2008-07-04 composições farmacêuticas e métodos para tratamento de distúrbios do olho seco

Country Status (15)

Country Link
US (2) US8541426B2 (pt)
EP (1) EP2175858B1 (pt)
JP (2) JP5649270B2 (pt)
KR (2) KR20120115413A (pt)
CN (1) CN101743009A (pt)
AR (1) AR067495A1 (pt)
AU (1) AU2008273804B2 (pt)
BR (1) BRPI0813553A2 (pt)
CA (1) CA2691914C (pt)
ES (1) ES2523303T3 (pt)
NZ (1) NZ582188A (pt)
RU (1) RU2445098C2 (pt)
TW (1) TWI364281B (pt)
WO (1) WO2009007839A1 (pt)
ZA (1) ZA201000991B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UA98449C2 (en) 2005-12-13 2012-05-25 Инсайт Корпорейшин Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2421867B1 (en) * 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Piperidine inhibitors of janus kinase 3
LT2432472T (lt) 2009-05-22 2020-02-10 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
BRPI1012159B1 (pt) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
WO2011017178A1 (en) * 2009-07-28 2011-02-10 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2011224484A1 (en) 2010-03-10 2012-09-27 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
CN103002875B (zh) 2010-05-21 2016-05-04 因塞特控股公司 Jak抑制剂的局部用制剂
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN104610264A (zh) * 2011-04-08 2015-05-13 辉瑞大药厂 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US11285040B2 (en) 2012-01-04 2022-03-29 Sight Sciences, Inc. Combination treatment systems
US9510972B2 (en) * 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
US10973680B2 (en) 2012-01-04 2021-04-13 Sight Sciences, Inc. Controller for dry eye treatment systems
US9724230B2 (en) 2012-01-04 2017-08-08 Sight Sciences, Inc. Dry eye treatment apparatus and methods
MY191357A (en) 2012-11-15 2022-06-19 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
UA120162C2 (uk) 2013-03-06 2019-10-25 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
PT3030227T (pt) 2013-08-07 2020-06-25 Incyte Corp Formas de dosagem de libertação prolongada para um inibidor de jak1
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
AU2015336396B2 (en) * 2014-10-22 2020-12-10 HLB Therapeutics Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
CN104857287B (zh) * 2015-04-21 2021-05-11 湖南中医药大学 一种治疗干眼症的中药滴眼液及其制备方法
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3484497A4 (en) * 2016-07-18 2020-01-01 Regentree, LLC METHOD FOR TREATING THE DRY EYE SYNDROME
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
KR20200129099A (ko) 2018-01-30 2020-11-17 인사이트 코포레이션 (1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
WO2019152232A1 (en) 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
US20220280515A1 (en) * 2019-08-07 2022-09-08 Rohto Pharmaceutical Co., Ltd. Ophthalmic Composition for Promoting Tear Secretion
WO2021132598A1 (ja) * 2019-12-27 2021-07-01 ロート製薬株式会社 水性組成物
TW202135822A (zh) * 2019-12-27 2021-10-01 日商樂敦製藥股份有限公司 水性組成物
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN114948991A (zh) * 2021-02-26 2022-08-30 复旦大学 氢化镁在制备防治干眼病相关眼表炎症药物中的应用
TW202329961A (zh) * 2021-11-30 2023-08-01 日商興和股份有限公司 新穎菸鹼醯胺化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5747474A (en) 1996-07-29 1998-05-05 Immune Modulation, Inc. Immunosuppression by administration of N6,N6 -disubstituted cAMP's, analogues thereof, and related nucleosides
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1162974A1 (en) * 1999-03-19 2001-12-19 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
US20020132767A1 (en) 2000-01-31 2002-09-19 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
AR035293A1 (es) * 2001-08-23 2004-05-05 Novartis Ag Composicion oftalmica.
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
RU2285511C2 (ru) * 2004-10-13 2006-10-20 НИИ ГБ им. Гельмгольца Средство для лечения синдрома сухого глаза
RU2290923C2 (ru) * 2005-03-04 2007-01-10 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения синдрома сухого глаза
WO2006108103A1 (en) * 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋキナーゼインヒビターおよびそれらの使用
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
JP5071374B2 (ja) * 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
AU2006273762A1 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
WO2007062459A1 (en) 2005-11-29 2007-06-07 Cytopia Research Pty Ltd Selective kinase inhibitors based on pyridine scaffold
JP2007314326A (ja) * 2006-05-26 2007-12-06 Mitsubishi Heavy Ind Ltd チョッパ折り方法及び装置
AR063141A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
AR066016A1 (es) * 2007-04-11 2009-07-15 Alcon Res Ltd Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica
CN101743009A (zh) * 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法

Also Published As

Publication number Publication date
JP2013147517A (ja) 2013-08-01
CA2691914C (en) 2012-06-26
KR101258316B1 (ko) 2013-04-30
AU2008273804B2 (en) 2014-07-10
WO2009007839A1 (en) 2009-01-15
EP2175858A1 (en) 2010-04-21
US20100267751A1 (en) 2010-10-21
US8541426B2 (en) 2013-09-24
TW200911265A (en) 2009-03-16
NZ582188A (en) 2012-03-30
TWI364281B (en) 2012-05-21
JP5649270B2 (ja) 2015-01-07
RU2009149687A (ru) 2011-07-10
US20130303557A1 (en) 2013-11-14
CN101743009A (zh) 2010-06-16
KR20100029823A (ko) 2010-03-17
JP2009046470A (ja) 2009-03-05
AU2008273804A1 (en) 2009-01-15
EP2175858B1 (en) 2014-09-10
RU2445098C2 (ru) 2012-03-20
ZA201000991B (en) 2010-12-29
KR20120115413A (ko) 2012-10-17
ES2523303T3 (es) 2014-11-24
AR067495A1 (es) 2009-10-14
CA2691914A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
BRPI0813553A2 (pt) composições farmacêuticas e métodos para tratamento de distúrbios do olho seco
BRPI0819331A2 (pt) Métodos e composições para o tratamento do olho seco
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0719918A2 (pt) Tratamento para olho seco usando-se testosterona e progestagênio
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0916323A2 (pt) composições antimicrobianas de liberação controlada e métodos para o tratamento de distúrbios do ouvido
BRPI0918670A2 (pt) composições e métodos para o tratamento de disordens mediados por ige
BRPI0921237A2 (pt) métodos e composições para o tratamento de distúrbios associados ao complemento
BRPI0819678A2 (pt) método para tratar cmt e distúrbios relacionados
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
BRPI0920326A2 (pt) composição e método para tratamento da síndrome do olho ressecado
BRPI0821731A8 (pt) composições cosméticas para conceder flimes superhidrofóbicos
BRPI0810561A2 (pt) métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0820084A2 (pt) Composição e método para aplicação de rímel seco
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]